App-Quantinova.ai

Results from plasmaMATCH trial treatment cohort A: A phase II trial of extended-dose fulvestrant in patients with an ESR1 mutation identified via ctDNA screening (CRUK/15/010)

Iain Macpherson - San Antonio Breast Cancer Symposium (SABCS) , 2019

Therapeutic Area

Disease

Drug/Treatment

N/A

Fulvestrant

Capivasertib (AZD5363) in combination with fulvestrant in PTEN-mutant ER+ metastatic breast cancer

Lillian M Smyth - San Antonio Breast Cancer Symposium (SABCS) , 2019

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Breast cancer

Fulvestrant

Results from plasmaMATCH trial treatment cohort B: A phase II trial of neratinib plus fulvestrant in ER positive breast cancer or neratinib alone in ER negative breast cancer in patients with a HER2 mutation identified via ctDNA screening (CRUK/15/010)

Andrew M Wardley - San Antonio Breast Cancer Symposium (SABCS) , 2019

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Breast cancer

Fulvestrant

Updated subgroup tumor response of abemaciclib plus aromatase inhibitor for hormone receptor positive (HR+), HER2 negative advanced breast cancer (MONARCH 3)

Joyce OShaughnessy - San Antonio Breast Cancer Symposium (SABCS) , 2019

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Breast cancer

Abemaciclib

Results from plasmaMATCH trial treatment cohort C: A phase II trial of capivasertib plus fulvestrant in ER positive breast cancer patients with an AKT1 mutation identified via ctDNA screening (CRUK/15/010)

Rebecca Roylance - San Antonio Breast Cancer Symposium (SABCS) , 2019

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Breast cancer

Fulvestrant

Results from plasmaMATCH trial treatment cohort D: A phase II trial of capivasertib in patients with an AKT activation basket mutation identified via ctDNA testing or tumour sequencing (CRUK/15/010)

Richard D Baird - San Antonio Breast Cancer Symposium (SABCS) , 2019

Therapeutic Area

Disease

Drug/Treatment

N/A

Long-term pooled safety analysis of palbociclib in combination with endocrine therapy for hormone receptor-positive/human epidermal growth factor receptor 2‒negative advanced breast cancer: An updated analysis

Richard S Finn - San Antonio Breast Cancer Symposium (SABCS) , 2019

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Breast cancer

Fulvestrant

Dose escalation and expansion study of lerociclib (G1T38), an oral CDK4/6 inhibitor, dosed with no drug holiday in combination with fulvestrant in patients with HR+/HER2- advanced breast cancer

Iurie Bulat - San Antonio Breast Cancer Symposium (SABCS) , 2019

Therapeutic Area

Disease

Drug/Treatment

Blood/haematological Diseases

Drug-induced liver injury

Fulvestrant

An integrated safety analysis of talazoparib monotherapy from five clinical trials (phase 1‑3) in advanced cancers

Joannes Ettl - San Antonio Breast Cancer Symposium (SABCS) , 2019

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Solid malignancies

Talazoparib

A phase Ib dose escalation study evaluating the mutant selective PI3K-alpha inhibitor GDC-0077 (G) in combination with letrozole (L) with and without palbociclib (P) in patients with PIK3CA-mutant HR+/HER2- breast cancer

Komal Jhaveri - San Antonio Breast Cancer Symposium (SABCS) , 2019

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Breast cancer

Palbociclib

Surgical margin involvement (<2mm) increases local and distant cancer recurrence

Sarah Michael - San Antonio Breast Cancer Symposium (SABCS) , 2019

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Breast cancer

N/A

Do surgical margins matter after mastectomy? A meta-analysis of 37,738 breast cancer patients in 33 studies

James Bundred - San Antonio Breast Cancer Symposium (SABCS) , 2019

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Breast cancer

N/A

The use of intraoperative ultrasound and guidewire placement to obtain low re-excision rates and increased accuracy of excision in impalpable breast lesions at the Cambridge Breast Unit

Primeera Wignarajah - San Antonio Breast Cancer Symposium (SABCS) , 2019

Therapeutic Area

Disease

Drug/Treatment

N/A

Exploratory analytical harmonization of PD-L1 immunohistochemistry assays in advanced triple-negative breast cancer: A retrospective substudy of IMpassion130

Hope Rugo - San Antonio Breast Cancer Symposium (SABCS) , 2019

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Triple-negative breast cancer

SP263

Efficacy of abemaciclib based on genomic alterations detected in baseline circulating tumor DNA from the MONARCH 3 study of abemaciclib plus nonsteroidal aromatase inhibitor

Matthew P Goetz - San Antonio Breast Cancer Symposium (SABCS) , 2019

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Solid malignancies

Abemaciclib

Kidins220 (kinase D interacting substrate 220) has a connection with neutrotrophic related factors, BDNF and NGF, in human breast cancer

Zhe Zhao - San Antonio Breast Cancer Symposium (SABCS) , 2019

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Breast cancer

N/A

Genetics and pathological correlation of BRCA status in patients of Asian origin diagnosed with breast or ovarian cancer; a UK Reference Genetics Laboratory Study

Aisling Longworth - San Antonio Breast Cancer Symposium (SABCS) , 2019

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Gynaecological cancer

N/A

Breast Cancer Index predicts benefit from extended endocrine therapy in HR+ breast cancer

John Bartlett - San Antonio Breast Cancer Symposium (SABCS) , 2019

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Breast cancer

Tamoxifen

Assessment of ESR1 genomic aberrations and their role in endocrine therapy resistance in breast cancer

Carlos Martinez-Perez - San Antonio Breast Cancer Symposium (SABCS) , 2019

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Breast cancer

N/A

Endocrine agents promote adverse responses in ER+ breast cancer cells through a mechanism involving PELP1

Michael Rees - San Antonio Breast Cancer Symposium (SABCS) , 2019

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Breast cancer

Fulvestrant

Filters

45280 Abstracts